Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach Antonio Garcia Molina

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain José Ramón González-Porras, Francisco Javier Parrondo García, Eduardo Anguita

Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients A. Garcia-Molina, Alos-Alminana